您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

林潔欣醫師

老年精神醫學、失智症、婦女精神醫學、成人精神醫學、生物精神醫學
  • 國語,英語,閩南語,客語
  • 教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院精神部 教授級主治醫師
    • 長庚大學醫學系 部定教授
    • 精神科專科醫師
    • 老年精神專科醫師
  • 學歷
    • 國立陽明大學醫學系畢業
    • 中國醫藥大學臨床醫學研究所博士畢業
  • 經歷
    • 高雄長庚醫院精神部一般精神科主任
    • 高雄市立凱旋醫院精神科住院醫師、主治醫師
    • 美國杜克醫學中心精神科臨床研究員
  • 學會與認證
    • 台灣精神醫學會專科醫師證書
    • 台灣老年精神醫學會專科醫師證書
    • Member of the International College of Neuropsychopharmacology
    • Member of the Asian Pacific Society for Neurochemistry/International Society for Neurochemistry
    • 「永信李天德醫藥基金會得獎人聯誼會」會員
  • 論文及期刊發表
    • Early Prediction of Clinical Response in Schizophrenia Patients Receiving Atypical Antipsychotic Zotepine.
      Journal of Clinical Psychiatry. 2007 Oct; 68(10):1522-7.
      Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY*
    • Factors affecting time to rehospitalization for patients with major depressive disorder.
      Psychiatry and Clinical Neurosciences. 2007 Jun; 61(3):249-54.
      Lin CH*, Chen YS, Lin CH, Lin KS
    • Factors affecting time to rehospitalization for Chinese schizophrenic patients in Taiwan.
      The Kaohsiung Journal of Medical Sciences 2008 Aug; 24:408–14.
      Lin CH, Chen CC, Wang SY, Lin SC, Chen MC, Lin CH*
    • Factors predicting transferal after psychiatric emergency management in the elderly.
      Psychiatry and Clinical Neurosciences. 2009 Dec; 63(6):741-6.
      Lin CH, Hsu CW, Teng CY, Sun PC, Hsu HC, Wung YT, Lin CH*
    • Mirtazapine-associated Hair Loss.
      Journal of Clinical Psychiatry. 2010 Oct;71(10):1400-1
      Lin CH, Hsu CW, Lin CH, Lane HY*
    • Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital.
      Psychiatry Research. 2010 Dec 30;180(2-3):74-9
      Lin CH, Chen MC, Chou LS, Lin CH, Chen CC, Lane HY*
    • Glutamate signaling in the pathophysiology and therapy of schizophrenia.
      Pharmacology, Biochemestry and Behavior. 2012 Feb; 100(4):665-77. (Invited review)
      Lin CH, Lane HY, Tsai G*
    • Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia.
      International Journal of Neuropsychopharmacology. 2012;15:897-906.
      Lin CH, Huang KH, Chang YC, Huang YC, Hsu WC, Lin CY, Chou HC, Tsai G, Lane HY*
    • Optimizing the early prediction model for symptomatic remission with acute treatment for schizophrenia.
      Journal of Clinical Psychopharmacology. 2012; 32: 773-777.
      Lin CH, Chou LS, Lin CH, Hsu CY, Chen CC, Lane HY*
    • NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer’s Disease.
      Current Neuropharmacology 2012; 10(3): 272-85. (Invited review)
      Huang YJ, Lin CH, Lane HY, Tsai G*
    • Potential Blood Biomarker for Disease Severity in the Taiwanese Population with Alzheimer’s disease.
      American Journal of Alzheimer's Disease and Other Dementias. 2013; 28(1): 75-83.
      Huang CW, Wang SJ, Wu SJ, Yang CC, Huang MW, Lin CH, Cheng HJ*
    • Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia.
      Schizophrenia Research. 2013 May; 146(1-3): 231-7.
      Lin CH, Huang CL, Chang YC, Chen PW, Lin CY, Tsai G, Lane HY*
    • Synergistic Effects of COMT and TPH2 on Social Cognition.
      Psychiatry. 2013; 76(3):273-294.
      Lin CH, Huang KH, Chang YC, Tsai G, Lane HY*
    • Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
      Biological Psychiatry. 2014 May 1; 75(9):678-85.
      Lin CH, Chen PK, Chang YC, Chou LJ, Chen YS, Tsai G, Lane HY*
    • Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals.
      Molecular Psychiatry. 2014 Jun; 19(6):636-637.
      Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai G, Lane HY*
    • NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease.
      Current Pharmaceutical Design. 2014 Oct; 20(32):5169-5179. (Invited review)
      Lin CH, Huang YJ, Lin CJ, Lane HY, Tsai G*
    • Sex-specific factors for bone density in patients with schizophrenia.
      International Clinical Psychopharmacology. 2015 Mar; 30(2):96-102.
      Lin CH, Lin CY, Huang TL, Wang HS, Chang YC, Lane HY*
    • Donepezil improved cognitive deficits in a patient with neurosyphilis.
      Clinical Neuropharmacology. 2015 Jul-Aug; 38(4):156-7.
      Wu YS, Lane HY, Lin CH*
    • Decreased mRNA expression for the two subunits of system xc- , SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia.
      Journal of Psychiatric Research. 2016 Jan; 72:58-63.
      Lin CH, Lin PP, Lin CY, Lin CH, Huang CH, Huang YJ, Lane HY*
    • Mania following ketamine abuse.
      Neuropsychiatric Disease and Treatment. 2016 Jan;12:237-239.
      Lu YY, Lin CH, Lane HY*
    • Spontaneous remission of ketamine-withdrawal related depression.
      Clinical Neuropharmacology. 2016 Jan-Feb;39(1):51-2.
      Lin PC, Lane HY, Lin CH*
    • Hypothyroidism may exacerbate valproate-related hyperammonemic delirium.
      Biomedicine (Taipei). 2016 Jun;6(2):31-32.
      Hung CC, Lin CH, Lane HY*
    • Effects of antipsychotics on bone mineral density in patients with schizophrenia: Gender differences.
      Clinical Psychopharmacology and Neuroscience. 2016 Aug;14(3):238-249. (Invited review)
      Chen CY, Lane HY, Lin CH*
    • Venous thromboembolism following dantrolene treatment for neuroleptic malignant syndrome.
      Clinical Psychopharmacology and Neuroscience. 2016 Nov;14(4):399-401.
      Chen PH, Lane HY, Lin CH*
    • β-hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: A case control study.
      Psychoneuroendocrinology. 2016 Nov;73:1-8.
      Huang YC, Lin PY, Lee Y, Wu CC, Hsu ST, Hung CF, Chen CC, Chong MY, Lin CH, Wang LJ
    • Brexpiprazole for the treatment of schizophrenia.
      Expert Opinion On Pharmacotherapy. 2017 Feb; 18(2):217-223. (Invited review)
      Hsu WY, Lane HY, Lin CH*
    • New treatment strategies of depression: Based on mechanisms related to neuroplasticity.
      Neural Plasticity 2017 Apr;2017:4605971. doi: 10.1155/2017/4605971. (Invited review)
      Huang YJ, Lane HY, Lin CH*
    • PICK1 genetic variation and cognitive function in patients with schizophrenia.
      Scientific Reports 2017 May 15;7(1):1889. doi: 10.1038/s41598-017-01975-y.
      Chen YT, Lin CH, Huang CH, Liang WM, Lane HY*
    • Gender differences in susceptibility to schizophrenia: potential implication of neurosteroids.
      Psychoneuroendocrinology 2017 Oct;84:87-93.
      Huang YC, Hung CF, Lin PY, Lee Y, Wu CC, Hsu ST, Chen CC, Chong MY, Lin CH, Wang LJ
    • Bupropion interferes with the image diagnosis of Parkinson disease.
      Neuropsychiatric Disease and Treatment 2017 Oct 19;13:2637-2639.
      Lin CH, Lane HY*
    • Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging.
      Scientific Reports 2017 Nov 1. 7:14849.
      Lin CH, Yang HT, Chiu CC, Lane HY*
    • Genetic biomarkers on cognitive aging.
      Frontiers in Psychiatry 2017 Nov;8:247.
      Lin CH, Lin Eugene, Lane HY*
    • Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation.
      Schizophrenia Research 2018 Feb;192:391-397.
      Wang LJ, Lin PY, Lee Y, Huang YC, Wu CC, Hsu ST, Chen CC, Chong MY, Lin CH, Hung CF*
    • Medications used for cognitive enhancement in patients with schizophrenia, bipolar Disorder, Alzheimer’s disease, and Parkinson’s disease.
      Frontiers in Psychiatry 2018 Apr 4;9:91.
      Hsu WY, Lane HY, Lin CH*
    • Brain stimulation in Alzheimer’s disease.
      Frontiers in Psychiatry 2018 May 22;9:201.
      Chang CH, Lane HY, Lin CH*
    • Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-Blind, placebo-controlled trial.
      Biological Psychiatry 2018 Sep 15;84(6):422-432.
      Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Lane HY*
    • Combination of G72 genetic variation and G72 protein level to detect schizophrenia: Machine learning approaches. (#Equal contribution)
      Frontiers in Psychiatry 2018 Nov 6;9:566.
      Lin Eugene#, Lin CH#, Lai YL, Huang CH, Huang YJ, Lane HY*
    • Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder.
      Journal of Affective Disorder 2019 Feb;245:1119-1125.
      Lin CH, Huang MW, Lin CH, Huang CH, Lane HY*
    • Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress.
      Frontiers in Psychiatry 2019 Feb 27;10:93.
      Lin CH, Lane HY*
    • Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.
      Scientific Reports 2019 Mar 7;9(1):3895.
      Lin CH, Lin CY, Wang HS, Lane HY*
    • Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning – A case series.
      Psychiatry and Clinical Neurosciences 2019 Jun;73(6):348.
      Tseng WT, Yeh JY, Lane HY, Lin CH*
    • Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
      Journal of Psychopharmacology 2019 Apr;33(4):436-448.
      Chang CH, Lane HY, Tseng PT, Chen SJ, Liu CY, Lin CH*
    • The Role of N-methyl-D-aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia.
      Frontiers in Pharmacology 2019 May 22;10:540.
      Lin CH, Lane HY*
    • Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): a Randomized, Double-blind, Placebo-controlled, 6-week Trial.
      Journal of Psychopharmacology 2019 Aug;33(8):1030-1033.
      Lin CH, Yang HT, Chen PK, Wang SH, Lane HY*
    • pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase
      Scientific Reports 2019 Sep 13;9(1):13221.
      Lin CH, Chiu CC, Huang CH, Yang HT, Lane HY*
    • D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment.
      Pharmacology, Biochemistry and Behavior 2019 Oct;185:172760.
      Lin CH, Yang HT, Lane HY*
    • C-Reactive Protein is Associated With Severity of Thought and Language Dysfunction in Patients With Schizophrenia.
      Neuropsychiatric Disease and Treatment 2019 Sep 10;15:2621-2627.
      Chang CH, Lane HY*, Liu CY, Cheng PC, Chen SJ, Lin CH*
    • Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: A nationwide population-based cohort study.
      Psychiatry Research 2019 Oct 2;281:112597.
      Chang CH, Lane HY*, Liu CY, Chen SJ, Lin CH*
    • Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant.
      Current Drug Targets 2020;21(6):610-615.
      Lin CH, Chen YM, Lane HY*
    • Editorial: Glutamate-related biomarkers for neuropsychiatric disorders.
      Frontiers in Psychiatry 2019 Dec 5;10:904.
      Lin CH, Hashimoto K, Lane HY*
    • Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia. (#Equal contribution)
      Scientific Reports 2019 Dec 11;9:18840.
      Lin CH#, Yang Sheng#, Huang YJ, Lane HY*
    • The Role of N-methyl-D-aspartate Receptor on Late-Life Depression.
      International Journal of Gerontology 2019 Dec;13(4):268-272. (Invited review)
      Hsieh MT, Lane HY, Lin CH*
    • Survey of NMDA receptor-related biomarkers for depression.
      Current Pharmaceutical Design 2020;26(2):228-235.
      Chen YM, Lin CH*, Lane HY*
    • Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches.
      International Journal of Molecular Sciences 2020 Feb 1;21(3):969.
      Lin Eugene, Lin CH*, Lane HY*
    • Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).
      Neuropsychiatric Disease and Treatment 2020 Feb 20;16:509-518.
      Lin CH, Yang HT, Chen PK, Wang SH, Lane HY*
    • Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia. (#Equal contribution)
      Neuropsychiatric Disease and Treatment 2020 Mar 20;16:771-780.
      Chang Jane#, Huang KH#, Lin CH*, Lane HY*
    • Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. (#Equal contribution)
      Journal of Psychopharmacology 2020 May;34(5):495-505.
      Chang CH#, Lin CH#, Liu CY, Chen SJ, Lane HY*
    • D-Glutamate and gut microbiota in Alzheimer’s disease.
      International Journal of Molecular Sciences 2020 Apr 11;21(8):2676.
      Chang CH, Lin CH*, Lane HY*
    • An ensemble approach to predict schizophrenia using protein data in the N-methyl-D-aspartate receptor (NMDAR) and tryptophan catabolic pathways.
      Frontiers in Bioengineering and Biotechnology 2020 Jun 4;8:569.
      Lin Eugene, Lin CH*, Hung CC, Lane HY*
    • Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design.
      Molecules 2020 Jul 16;25(14):3250.
      Lin Eugene, Lin CH*, Lane HY*
    • D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density.
      Scientific Reports 2020 Aug 6;10(1):13236.
      Chiang TI, Lane HY, Lin CH*
    • Trough melatonin levels differ between early and late phases of Alzheimer disease.
      Clinical Psychopharmacology and Neuroscience 2021 Feb 28;19(1):135-144.
      Lin CH, Chiu CC, Lane HY*
    • Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease.
      International Journal of Molecular Sciences 2021 Feb 25;22(5):2283.
      Cheng YJ, Lin CH*, Lane HY*
    • Plasma D-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches. (#Equal contribution)
      Journal of Psychopharmacology 2021 Mar;35(3):265-272.
      Chang CH#, Lin CH#, Liu CY, Huang CS, Chen SJ, Lin WC, Yang HT, Lane HY*：
    • Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease.
      International Journal of Molecular Sciences 2021 Mar 9;22(5):2761.
      Chang CH, Lin CH*, Lane HY*
    • Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions.
      Scientific Reports 2021 Mar 25;11(1):6922.
      Lin Eugene, Lin CH*, Lane HY*
    • Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial.
      JAMA Network Open 2021 Apr 1;4(4):e216156.
      Lin CH, Chen PK, Wang SH, Lane HY*
    • Prediction of Functional Outcomes of Schizophrenia with Genetic Biomarkers Using a Bagging Ensemble Machine Learning Method with Feature Selection.
      Scientific Reports 2021 May 13;11(1):10179.
      Lin Eugene, Lin CH*, Lane HY*
    • Reply: Trough melatonin levels have no physiological or clinical relevance.
      Clinical Psychopharmacology and Neuroscience 2021 May 31;19(2):393.
      Lin CH, Lane HY*
    • Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial.
      International Journal of Neuropsychopharmacology 2021 May 18;24(5):392-399.
      Lane HY, Tu CH, Lin WC, Lin CH*
    • Molecular Basis of Late-Life Depression.
      International Journal of Molecular Sciences 2021 Jul 10;22(14):7421.
      Kuo CY, Lin CH*, Lane HY*
    • Novel Biomarkers of Alzheimer’s Disease: Based upon NMDAR Hypoactivation and Oxidative Stress.
      Clinical Psychopharmacology and Neuroscience 2021 Aug 31;19(3):423-433.
      Chiang TI, Yu YH, Lin CH*, Lane HY*
    • Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry (#Equal contribution).
      Molecules 2021 Jul 23;26(15):4457.
      Lin CH#, Su H#, Hung CH, Lane HY*, Shiea J*
    • Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease.
      International Journal of Molecular Sciences 2021 Jul 24;22(15):7911.
      Lin Eugene, Lin CH*, Lane HY*
    • Novel therapeutic approaches for Alzheimer’s disease: an updated review.
      International Journal of Molecular Sciences 2021 Jul 30;22(15):8208.
      Yu TW, Lane HY*, Lin CH*
    • The relationships between hyperprolactinemia, metabolic disturbance, and sexual dysfunction in patients with schizophrenia under olanzapine treatment (#Equal contribution).
      Frontiers in Pharmacology 2021 Aug 5;12:718800.
      Wu TH#, Lin CH#, Goh KK, Chen YA, Chen CH, Lane HY, Lu ML
    • From menopause to neurodegeneration - molecular basis and potential therapy.
      International Journal of Molecular Sciences 2021 Aug 11;22(16):8654.
      Cheng YJ, Lin CH*, Lane HY*
    • Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment.
      International Journal of Molecular Sciences 2021 Sep 8;22(18):9718.
      Hung CC, Lin CH*, Lane HY*
    • D-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia.
      International Journal of Molecular Sciences 2021 Oct 9;22(20):10917.
      Cheng YJ, Lin CH*, Lane HY*
    • Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments.
      Clinical Psychopharmacology and Neuroscience 2021 Nov 30;19(4):577-588.
      Lin Eugene, Lin CH*, Lane HY*
    • Plasma glutathione levels decreased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study.
      Antioxidants 2021 Nov 19;10(11):1839.
      Lin CH, Lane HY*
    • Logistic ridge regression to predict bipolar disorder using mRNA expression levels in the N-methyl-D-aspartate receptor genes.
      Journal of Affective Disorders 2022 Jan 15;297:309-313.
      Lin Eugene, Lin CH*, Lane HY*
    • Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms.
      Pharmacology, Biochemistry and Behavior 2022 Feb;213:173335.
      Chen YM, Lin CH*, Lane HY*
    • Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial.
      International Journal of Neuropsychopharmacology 2022 Aug 4;25(7):545-555.
      Lin CH, Wang SH, Lane HY*
    • A bagging ensemble machine learning framework to predict overall cognitive function of schizophrenia patients with cognitive domains and tests.
      Asian Journal of Psychiatry 2022 Mar;69:103008.
      Lin Eugene, Lin CH*, Lane HY*
    • De Novo Peptide and Protein Design Using Generative Adversarial Networks: An Update.
      Journal of Chemical Information and Modeling 2022 Feb 28;62(4):761-774.
      Lin Eugene, Lin CH*, Lane HY*
    • Suicide ideation among outpatients with alcohol use disorder.
      Behavioural Neurology 2022 Feb 12;2022:4138629.
      Hsu WY, Lin CH*, Lane HY*
    • Blood D-amino acid oxidase (DAO) levels increased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study.
      International Journal of Neuropsychopharmacology 2022 Aug 16;25(8):660-665.
      Lin CH, Lane HY*
    • Diagnosing Alzheimer’s disease specifically and sensitively with pLG72 and cystine/glutamate antiporter SLC7A11 as blood biomarkers.
      International Journal of Neuropsychopharmacology 2022 Aug 20:pyac053.
      Lane HY, Lin CH*
    • Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.
      CNS Drugs 2022 Nov;36(11):1143-1153.
      Kuo CY, Lin CH*, Lane HY*
    • Endogenous Antioxidants Predicted Outcome and Increased after Treatment: a Benzoate Dose-finding, Randomized, Double-blind, Placebo-controlled Trial for Alzheimer's Disease.
      Psychiatry and Clinical Neurosciences 2022 Nov 6. doi: 10.1111/pcn.13504. Online ahead of print.
      Lane HY, Wang SH, Lin CH*
    • Ketamine, benzoate, and sarcosine for treating depression.
      Neuropharmacology 2023 Feb 1;223:109351.
      Cheng YJ, Lin CH*, Lane HY*